RT Journal Article
T1 An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures
A1 Collord, Grace
A1 Tarpey, Patrick
A1 Kurbatova, Natalja
A1 Martincorena, Inigo
A1 Morán, Sebastián
A1 Castro, Manuel
A1 Nagy, Tibor
A1 Bignell, Graham
A1 Maura, Francesco
A1 Young, Matthew D.
A1 Berna, Jorge
A1 Castro Tubío, José Manuel
A1 McMurran, Chris E.
A1 Young, Adam M.H.
A1 Sanders, Mathijs
A1 Noorani, Imran
A1 Price, Stephen J.
A1 Watts, Colin
A1 Leipnitz, Elke
A1 Kirsch, Matthias
A1 Schackert, Gabriele
A1 Pearson, Danita
A1 Devadass, Abel
A1 Ram, Zvi
A1 Collins, V. Peter
A1 Allinson, Kieren
A1 Jenkinson, Michael D.
A1 Zakaria, Rasheed
A1 Syed, Khaja
A1 Hanemann, C. Oliver
A1 Dunn, Jemma
A1 McDermott, Michael W.
A1 Kirollos, Ramez W.
A1 Vassiliou, George S.
A1 Esteller, Manel
A1 Behjati, Sam
A1 Brazma, Alvis
A1 Santarius, Thomas
A1 McDermott, Ultan
K1 CNS cancer
K1 Genetics
AB Anaplastic meningioma is a rare and aggressive brain tumor characterised by intractable recurrences and dismal outcomes. Here, we present an integrated analysis of the whole genome, transcriptome and methylation profiles of primary and recurrent anaplastic meningioma. A key finding was the delineation of distinct molecular subgroups that were associated with diametrically opposed survival outcomes. Relative to lower grade meningiomas, anaplastic tumors harbored frequent driver mutations in SWI/SNF complex genes, which were confined to the poor prognosis subgroup. Aggressive disease was further characterised by transcriptional evidence of increased PRC2 activity, stemness and epithelial-to-mesenchymal transition. Our analyses discern biologically distinct variants of anaplastic meningioma with prognostic and therapeutic significance
PB Nature Publishing Group
SN 2045-2322
YR 2018
FD 2018
LK http://hdl.handle.net/10347/22643
UL http://hdl.handle.net/10347/22643
LA eng
NO Collord, G., Tarpey, P., Kurbatova, N. et al. An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures. Sci Rep 8, 13537 (2018). https://doi.org/10.1038/s41598-018-31659-0
NO This work was supported by the Wellcome Trust, Cancer Research UK, Meningioma UK and Tadhg and Marie-Louise Flood. U.M. was personally supported by a Cancer Research UK Clinician Scientist Fellowship; G.C. by a Wellcome Trust Clinical PhD Fellowship (WT098051); F.M. by A.I.L. (Associazione Italiana Contro le Leucemie-Linfomi e Mieloma ONLUS) and by S.I.E.S. (Società Italiana di Ematologia Sperimentale); S.B. was funded by a Wellcome Trust Intermediate Clinical Research Fellowship and a St. Baldrick’s Foundation Robert J. Arceci Innovation Award. J.M.C.T. is supported by ERC Starting Grant StG-2016_716290_SCUBA CANCERS and by MINECO Grants RYC 2014 14999 and SAF2015-66368-P. J.B. was funded by the charity Brain Tumour Research
DS Minerva
RD 24 abr 2026